In short, men (age > 50 years) with histologically proven prostate cancer (PCa) and progressive disease after local therapy (PSA > 0.2 μg/l), with a PSA doubling time of <6 months and no curable treatment options left (e.g., surgery or external beam radiotherapy), were eligible for this trial. The gene discussed is KLK3; the disease is prostate cancer.